Seres Therapeutics (MCRB) Upgraded to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a buy rating in a research note issued to investors on Tuesday. The firm currently has $12.00 price objective on the biotechnology company’s stock.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other equities analysts have also recently issued reports on the company. Citigroup initiated coverage on Seres Therapeutics in a report on Thursday, October 12th. They set a positive rating and a $19.00 price target on the stock. CIBC initiated coverage on Seres Therapeutics in a report on Friday, October 13th. They set an outperform rating and a $19.00 price target on the stock. Oppenheimer initiated coverage on Seres Therapeutics in a report on Thursday, October 12th. They set an outperform rating and a $19.00 price target on the stock. Seaport Global Securities restated a buy rating and set a $20.00 price target on shares of Seres Therapeutics in a report on Friday, October 6th. Finally, ValuEngine cut Seres Therapeutics from a hold rating to a sell rating in a report on Thursday, September 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. Seres Therapeutics has an average rating of Buy and a consensus price target of $18.00.

Shares of Seres Therapeutics (NASDAQ:MCRB) traded down $0.03 during mid-day trading on Tuesday, reaching $9.87. The company had a trading volume of 111,200 shares, compared to its average volume of 208,769. Seres Therapeutics has a 1-year low of $8.85 and a 1-year high of $17.42. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.11.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.22. The business had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $17.29 million. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The firm’s revenue was up 76.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.46) earnings per share. sell-side analysts anticipate that Seres Therapeutics will post -2.33 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System lifted its holdings in shares of Seres Therapeutics by 1.1% in the 2nd quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock worth $410,000 after purchasing an additional 400 shares in the last quarter. Teachers Advisors LLC lifted its holdings in shares of Seres Therapeutics by 1.2% in the 2nd quarter. Teachers Advisors LLC now owns 38,758 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 450 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Seres Therapeutics by 0.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 91,543 shares of the biotechnology company’s stock worth $1,035,000 after purchasing an additional 494 shares in the last quarter. Parametric Portfolio Associates LLC lifted its holdings in shares of Seres Therapeutics by 2.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 21,915 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 580 shares in the last quarter. Finally, American International Group Inc. lifted its holdings in shares of Seres Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 727 shares in the last quarter. Institutional investors own 77.83% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://stocknewstimes.com/2017/12/06/seres-therapeutics-mcrb-upgraded-to-buy-at-zacks-investment-research.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply